Clinical Trials | October 13, 2025
Roche to present latest cancer care data at ESMO 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Importantly, the combination of giredestrant and everolimus was well tolerated
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Subscribe To Our Newsletter & Stay Updated
